Key facts
- Notable investors include Leader Venture Capital, Jiangsu Industrial Technology Research Institute.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kaizhen Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kaizhen Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kaizhen Bio
Developer of biomedical compounds intended for pharmaceutical research and experimental development purposes. The company's platform focuses on non-clinical biomedical research and technical services, featuring capabilities such as molecular compound screening, pharmacological evaluation, and formulation development, serving pharmaceutical companies and research institutions to accelerate early-stage drug discovery, improve experimental accuracy, and reduce time-to-market for innovative therapeutic solutions.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Kaizhen Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kaizhen Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kaizhen Bio in its N-PORT filings yet. We sweep new filings monthly.